EUVIMEDEUVIMED entdecken
VergleichsstudieKohortenstudie

Endoscopic sleeve gastroplasty versus oral semaglutide for obesity: a real-world comparative cohort study

Nitin Jagtap iD, Aman Golchha, Anudeep Katrevula iD, Shujaath Asif iD, Hardik Rughwani iD, Krithi Krishna Koduri iD, Priyanka Balenki, Rakesh Kalapala, D Nageshwar Reddy

Endoscopy · 01.10.2026 · 58 (10) · 1084-1090

DOI: 10.1055/a-2891-4165 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Endoscopy, erschienen am 01.10.2026. Verfasst von Nitin Jagtap und 8 weiteren Autor:innen. Beteiligte Einrichtung: Asian Institute of Gastroenterology, Department of Medical Gastroenterology, India, Hyderabad. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Gastroplasty, Obesity, Hypoglycemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Endoscopic sleeve gastroplasty (ESG) and semaglutide are established therapies for obesity. However, comparative real-world data remain limited. We compared the effectiveness and safety of ESG versus oral semaglutide 14 mg in adults with obesity. In a real-world retrospective comparative cohort study between January 2024 and April 2025, adults aged 18–65 years with body mass index (BMI) ≥30, or ≥27 kg/m2 with obesity-related comorbidity, treated with either ESG or oral semaglutide 14mg daily, and having 6-months’ follow-up were included. Primary endpoint was percentage total body weight loss (%TBWL) at 6 months. Secondary outcomes included treatment responder rates, adverse events, and 12-month weight outcomes. Analyses included Welch’s two-sample t-tests, analysis of covariance adjusted for age, sex, baseline BMI, and diabetes, inverse probability of treatment weighting (IPTW), and 1:1 propensity score matching. 150 patients were included (ESG n=50; semaglutide n=100). Baseline characteristics were broadly similar between groups. At 6 months, mean %TBWL was significantly higher with ESG than semaglutide (12.72±5.67% vs 8.67±3.84%, P=0.0001) that remained after covariate adjustment (adjusted mean difference 4.04%, P=0.0001), IPTW analysis (P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like PeptidesGastroplastyObesityHypoglycemic AgentsHumansSemaglutideFemaleMaleMiddle AgedAdultRetrospective StudiesAdministration, OralWeight LossTreatment OutcomeAgedYoung AdultAdolescent

Substanzen

SemaglutideGlucagon-Like PeptidesHypoglycemic Agents

Autor:innen und Institutionen

  • Asian Institute of Gastroenterology, Department of Medical Gastroenterology, India, Hyderabad.

ORCID-Profile: Nitin Jagtap, Anudeep Katrevula, Shujaath Asif, Hardik Rughwani, Krithi Krishna Koduri

Zitieren

APA

Jagtap, N., Golchha, A., Katrevula, A., Asif, S., Rughwani, H., Koduri, K. K., Balenki, P., Kalapala, R., & Reddy, D. N. (2026). Endoscopic sleeve gastroplasty versus oral semaglutide for obesity: a real-world comparative cohort study. Endoscopy, 58(10), 1084-1090. https://doi.org/10.1055/a-2891-4165

Vancouver

Jagtap N, Golchha A, Katrevula A, Asif S, Rughwani H, Koduri KK, et al. Endoscopic sleeve gastroplasty versus oral semaglutide for obesity: a real-world comparative cohort study. Endoscopy. 2026;58(10):1084-1090. doi:10.1055/a-2891-4165

BibTeX
@article{Jagtap2026,
  author = {Jagtap, Nitin and Golchha, Aman and Katrevula, Anudeep and Asif, Shujaath and Rughwani, Hardik and Koduri, Krithi Krishna and Balenki, Priyanka and Kalapala, Rakesh and Reddy, D Nageshwar},
  title = {Endoscopic sleeve gastroplasty versus oral semaglutide for obesity: a real-world comparative cohort study},
  journal = {Endoscopy},
  year = {2026},
  volume = {58},
  number = {10},
  pages = {1084--1090},
  doi = {10.1055/a-2891-4165}
}
Kostenlos starten →